US 10,888,603 B2
Methods of treating cancer cells expressing tumor-associated integrins
Karl Dane Wittrup, Boston, MA (US); Darrell J. Irvine, Arlington, MA (US); Cary Francis Opel, Somerville, MA (US); Kelly Dare Moynihan, Allston, MA (US); Jennifer R. Cochran, Stanford, CA (US); and Byron Hua Kwan, Seattle, WA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Appl. No. 16/76,597
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); and The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Feb. 10, 2017, PCT No. PCT/US2017/017365
§ 371(c)(1), (2) Date Aug. 8, 2018,
PCT Pub. No. WO2017/139570, PCT Pub. Date Aug. 17, 2017.
Claims priority of provisional application 62/294,755, filed on Feb. 12, 2016.
Prior Publication US 2019/0054145 A1, Feb. 21, 2019
Int. Cl. A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 38/16 (2006.01); C07K 16/28 (2006.01); A61K 39/12 (2006.01); A61K 47/64 (2017.01); A61K 47/60 (2017.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01)
CPC A61K 38/2013 (2013.01) [A61K 38/16 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/3955 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 47/60 (2017.08); A61K 47/643 (2017.08); A61K 47/6813 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/3053 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/55533 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/6025 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/6093 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C12N 2710/20034 (2013.01)] 35 Claims
 
1. A method for treating a cancer comprising tumor cells expressing a tumor-associated integrin in a subject, comprising administering to the subject a therapeutically effective amount of:
(a) interleukin (IL)-2;
(b) an integrin-binding-Fc fusion protein which binds to the tumor cells expressing the tumor-associated integrin; and
(c) a cancer vaccine,
wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold, and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain.